首页 | 本学科首页   官方微博 | 高级检索  
检索        

内蒙古乌兰察布地区布鲁氏菌体外药物敏感性及耐药机制分析
引用本文:刘志国,王妙,李晓燕,塔娜,赵鸿雁,朴东日,赵忠志,李振军.内蒙古乌兰察布地区布鲁氏菌体外药物敏感性及耐药机制分析[J].中国人兽共患病杂志,2019,35(5):393-398.
作者姓名:刘志国  王妙  李晓燕  塔娜  赵鸿雁  朴东日  赵忠志  李振军
作者单位:1.中国疾病预防控制中心传染病预防控制所,传染病预防控制国家重点实验室,北京 102206;
2.内蒙古自治区综合疾病预防控制中心,呼和浩特 010031;
3.乌兰察布市地方病防治中心,乌兰察布 012000
基金项目:传染病重大专项(No.2017ZX10303401),生物安全重点专项(No.2017YFC1200303),生物安全重点专项(No.2016YFC1200701)和内蒙古自治区自然科学基金(No.2018MS08004)联合资助
摘    要:目的调查内蒙古乌兰察布地区分离布鲁氏菌的抗生素药物敏感(耐受)性特征。方法采用E-test法测定了85株布鲁氏菌对13种临床常用药物的敏感性;同时,对利福平和阿奇霉素的耐药机制进行了初步探讨;并采用K-B法对来自全国的149株羊种布鲁氏菌对复方新诺明和利福平的敏感性进行了筛查。结果试验表明布鲁氏菌对阿奇霉素、复方新诺明和利福平耐药菌株数分别为100%(85/85),7.0%(6/85)和1.0%(1/85)。所有菌株对司帕沙星、米诺环素、多西环素、四环素、链霉素、庆大霉素、左氧氟沙星、环丙沙星、头孢吡肟及头孢哌酮舒巴坦均表现为敏感;司帕沙星、米诺环素的MIC90值(0.032μg/mL)最低。所有阿奇霉素耐药菌株的23S rRNA基因的第2632位碱基表现为T→C单位点突变,布鲁氏菌23S rRNA转肽酶中心的T/C点突变可能是一种羊种布鲁氏菌对阿奇霉素耐药的分子机制。K-B法筛查结果表明所有菌株对利福平敏感,25.5%(38/149)的菌株对复方新诺明耐药,耐药菌株分布于18个省市区。结论乌兰察布地区羊种布鲁氏菌耐药较为严重,应定期进行药物敏感性监测。推荐司帕沙星和米诺环素作为一线布病治疗药物。

关 键 词:布鲁氏菌  药物敏感性  耐药机制
收稿时间:2018-08-08

In vitro drugs susceptibility and resistance mechanism investigation of Brucella isolates from Ulanqab region of Inner Mongolia
LIU Zhi-guo,WANG Miao,LI Xiao-yan,TA Na,ZHAO Hong-yan,PIAO Dong-ri,ZHAO Zhong-zhi,LI Zhen-jun.In vitro drugs susceptibility and resistance mechanism investigation of Brucella isolates from Ulanqab region of Inner Mongolia[J].Chinese Journal of Zoonoses,2019,35(5):393-398.
Authors:LIU Zhi-guo  WANG Miao  LI Xiao-yan  TA Na  ZHAO Hong-yan  PIAO Dong-ri  ZHAO Zhong-zhi  LI Zhen-jun
Institution:1. National Institute of Infectious Diseases Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China;2. Inner Mongolia Autonomous Region Central for Comprehensive Disease Control and Prevention, Huhhot 010031, China;3. Ulanqab Center for Endemic Disease Control and Prevention, Ulanqab 012000, China
Abstract:The aims of this study is to investigate the antibiotics susceptibilities profiles of Brucella strains obtained from Ulanqab of Inner Mongolia. The susceptibilities of 85 B.melitensis strains to 13 common used antibiotics was detected by E-test method, and resistance mechanism of rifampin and azithromycin were preliminarily examined. Subsequently, susceptibility of 149 B. melitensis strains from China to cotrimoxazole and rifampin were tested using K-B method. The study found that the number of strains resistance to azithromycin, cotrimoxazole and rifampin was 100% (85/85),7.0% (6/85) and 1.0% (1/85), respectively. All of the tested isolates were susceptible to minocycline, sparfloxacin, doxycycline, tetracycline, streptomycin, gentamicin, levofloxacin, ciprofloxacin, cefotaxime and cefoperazone sulbactam. Of them, aparfloxacin and minocycline shows the lowest MIC90 value (0.032 μg/mL). The polymorphism of 2632 base T/C in the 23S rRNA of Brucella spp. was a potential molecular mechanism of B. melitensis in this study resistant to azithromycin. K-B method screen data indicated that all of 149 strains were susceptible to rifampin. Moreover, 25.5% (38/149) of strains were resistance to cotrimoxazole and these resistance strains were distributed in 18 different provinces of China. In conclusion, the situation of antibiotics resistance of B. melitensis clinical isolates was rather serious in Ulanqab region, surveillance of changes in antibiotic susceptible should be regular implemented. Moreover, we suggest that both minocycline and sparfloxacin could be as first-line agents for treatment of brucellosis.
Keywords:B  melitensis  drug susceptibility  resistance mechanism  
本文献已被 CNKI 维普 等数据库收录!
点击此处可从《中国人兽共患病杂志》浏览原始摘要信息
点击此处可从《中国人兽共患病杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号